Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024
April 18, 2024 08:00 ET
|
Ardelyx, Inc.
WALTHAM, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Ardelyx, Inc. Reports Employment Inducement Grants
March 28, 2024 16:05 ET
|
Ardelyx, Inc.
WALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
March 25, 2024 08:00 ET
|
Ardelyx, Inc.
WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Ardelyx, Inc. Reports Employment Inducement Grants
March 12, 2024 16:35 ET
|
Ardelyx, Inc.
WALTHAM, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Ardelyx to Participate at the Cowen 44th Annual Health Care Conference
February 27, 2024 08:00 ET
|
Ardelyx, Inc.
WALTHAM, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 22, 2024 16:01 ET
|
Ardelyx, Inc.
Strong commercial performance of IBSRELA continues, ending FY 2023 with $80.1 million in net product sales revenue; 2024 net product sales revenue currently expected to be between $140.0 to $150.0...
Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
February 01, 2024 08:00 ET
|
Ardelyx, Inc.
WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Ardelyx, Inc. Reports Employment Inducement Grants
January 12, 2024 07:56 ET
|
Ardelyx, Inc.
WALTHAM, Mass., Jan. 12, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
January 08, 2024 08:00 ET
|
Ardelyx, Inc.
Company achieved significant commercial progress in 2023 IBSRELA® now expected to generate greater than $1.0 billion in annual U.S. net product sales revenue at peak Webcast scheduled for 7:00 PM ET...
Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8
January 03, 2024 08:03 ET
|
Ardelyx, Inc.
WALTHAM, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...